Jefferies Upgrades Regeneron Pharma (REGN) to Buy

Jefferies analyst Akash Tewari upgraded Regeneron Pharma (NASDAQ: REGN) from Hold to Buy with a price target of $925.00 (from $675.00).

The analyst comments "Dupi well exceeded buyside bar (20% COPD exac. reduc.), showing 30% reduc. & 83mL FEV1 benefit over pbo. We think COPD could be $4Bn opp for Dupi (incr. total Dupi PS to $19.2Bn). We also incr. REGN's IL-33 PS to $2Bn given signal in non-smokers. Additionally, keep an eye on REGN's LAG-3 & PSMAxCD28 (we model risk-adj PS of $1.1Bn & $379m, respectively). Next up? HD Eylea switch
+ clarity on Eylea IP case mid-year + IRA impact on HD Eylea. BUY (PT $675->$925)."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $802.16 yesterday.

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group
• New Street Research Upgrades Micron Technology (MU) to Buy
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'